EL7.AI
Mergers & AcquisitionsMedium•16 November 2026•
1 min read

Johnson & Johnson Acquires Ollin Biosciences for $2.2 Billion

Key Facts

1Johnson & Johnson announced the acquisition of Ollin Biosciences in a deal valued at $2.2 billion.

Johnson & Johnson announced the acquisition of Ollin Biosciences in a deal valued at $2.2 billion. Investing.com reported that the acquisition is part of Johnson & Johnson's strategic expansion in the biosciences sector to strengthen its pipeline.

JNJ closed at $285.75 on November 13, 2026, with the stock reaching a day high of $288.11 and a low of $281.68 during that session. This multi-billion dollar acquisition by the healthcare leader signals a continued intent to drive growth through strategic biotech investments.

Open on chart